Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms.

Itır Şirinoğlu Demiriz, Mehmet Hanifi Kazanci, Esra Menfaatli, Davoud Jafari-Gharabaghlou, Nosratollah Zarghami

Molecular biology reports 2023 Jul

filter terms:

Janus kinase 2 (JAK2) V617F gene mutation is an important marker for the diagnosis of Philadelphia negative Myeloproliferative neoplasms (MPN) which is subdivided into Polycythemia Vera (PV), Primary Myelofibrosis (PMF), and Essential Thrombocythemia (ET). The aim here is to investigate the JAK2 allele burden of the patients diagnosed with the subgroups of MPN and to demonstrate the alterations of hematological parameters and spleen size between diagnosis and 6 months of treatment. A total of 107 patients with the diagnosis of MPN and negative Philadelphia chromosome, 51 males and 56 females with a mean age of 59,74 ± 16,41 years, were included in the study. Diagnosis of MPN was based on the World Health Organization (WHO) criteria. Subgroups of MPN distributed as 49,5% ET, 46,7% PV, and 3,8% PMF. Findings such as the age of the patients, JAK-2 allele burden, and laboratory findings of splenomegaly were examined at the time of diagnosis, 3rd month, and 6th month. JAK2 allele burden and spleen size were re-evaluated in 6th month. Our study confirmed the findings of high Hb, HCT, and RBC but low platelet values in PV patients with high JAK2 allele burden with respect to other groups, a positive correlation between JAK2 allele burden and LDH. A novel finding of our study is, that there is not any reducing effect of the phlebotomy on JAK2 allele burden in PV patients whether they receive phlebotomy or not. Evaluation of the spleen size alteration during 6 months within the subgroups demonstrated a decrease in PV and ET groups whereas no statistically significant difference was found in the PMF group. © 2023. The Author(s), under exclusive licence to Springer Nature B.V.

Citation

Itır Şirinoğlu Demiriz, Mehmet Hanifi Kazanci, Esra Menfaatli, Davoud Jafari-Gharabaghlou, Nosratollah Zarghami. Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms. Molecular biology reports. 2023 Jul;50(7):5687-5695